Nuvilex has contracted with Inno Biologics to generate cell clones that will be the basis of the Nuvilex’s future Phase III cancer clinical trials. Financial and other terms of the pact were not disclosed. From Inno’s clones, those with the highest enzyme activity that activates the cancer drug ifosfamide will be advanced through further testing. Eventually the best cell clones will be propagated and one will be prepared for encapsulation as part of the Company’s treatment for...